



BETA DRUGS LIMITED BECOMES THE FIRST INDIAN COMPANY TO RECEIVE APPROVAL FOR METHOTREXATE ORAL SOLUTION

Beta Drugs Limited, one of the leading manufacturers of Oncology medicines in India, proudly announces that it has received approval from the Drug Controller General of India (DCGI) for the launch of Methotrexate Solution for Oral Use.

This approval makes BDL the first company in India to introduce **Methotrexate Oral Solution**, a patient-friendly and **bioequivalent alternative** to existing tablet form. The product is indicated for use in **acute lymphoblastic leukemia (ALL), lymphomas, various solid tumors, Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), and Psoriasis Vulgaris including Chronic Plaque Psoriasis, Erythrodermic Psoriasis, Psoriatic Arthritis and Pustular Psoriasis.**

Methotrexate is a globally recognized therapy in oncology and autoimmune disorders. Traditionally available as tablets or injections, it often poses challenges in dosing and administration—especially for **pediatric, geriatric, and chronic-care patients.** The oral solution offers an easy-to-administer, accurately dosed, and bioequivalent alternative, improving **compliance, convenience, and safety** under medical supervision.

This first-to-market approval represents a major step forward to expand beyond oncology into autoimmune therapy segments. The company has a strong presence in Oncology and dermatology. This launch is a significant step in expanding company's portfolio and strengthening leadership in oncology & Dermatology segment. Its need of the hour to improve patient compliance for a drug which has therapeutic and clinical benefit for various disease conditions.

Global methotrexate market is ever growing owing to lesser number of alternatives with same therapeutic benefit for patients of ALL, autoimmune and inflammatory diseases. The introduction of an oral solution provides new opportunities in pediatric, hospital, and chronic-care segments, creating potential for strong domestic and export growth.

This first-to-market approval underscores company's commitment to developing differentiated and patient-centric solutions that improve both treatment access and quality of life. It will further build up on its track record of delivering affordable, high-quality therapies for cancer and other critical conditions.

Beta Drugs Limited

Company Secretary
ACS - 24684

CIN No.: L24230HP2005PLC028969

Admin. Office : SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

Website :- www.betadrugslimited.com

E-Mail :- info@betadrugslimited.com